G Curigliano MD PhD Profile picture
Giuseppe Curigliano, MD, PhD, Professor at University of Milan and Head of Phase I Division at IEO, ESMO Council Member, Tweets are my own
Oct 31, 2022 12 tweets 5 min read
Sponsored by @Roche,
I would like to share a Tweetorial about recent important advances in the management of advanced/metastatic triple negative breast cancer (mTNBC)

#Tweetorial #Oncology #Cancer #Diagnosis #TNBC #Immunotherapy #PDL1 TNBC is a challenging disease to treat due to its aggressive behavior, heterogeneity, and the lack of universal actionable targets. mTNBC is commonly diagnosed at a younger age than other BC subtypes and its prognosis is poor, with a median survival of <2 years.